BMD

Denosumab Increased Bone Mineral Density in Men With Nonmetastatic Prostate Cancer

Presented at EAU on March 23, 2009 The drug Denosumab has shown itself both easy to tolerate by patients as well highly able to increases bone mineral density (BMD) when compared with placebo in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT). The results of this multi-centre, randomized, double-blind, placebo-controlled, phase 3 study [...]

By Malecare|2009-04-01T09:40:05-04:00April 1st, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

Denosumab for Bone Mineral Density (BMD)

Amgen just completed, with positive results, a three-year Phase 3 placebo-controlled trial which evaluated denosumab for the treatment of bone loss (reduction of bone mineral density –BMD) in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. One of the more common and significant side effects of ADT is loss of BMD. This loss [...]

By Malecare|2008-08-01T10:40:12-04:00August 1st, 2008|Advanced Prostate Cancer, Bone Mineral Density, Drugs & Treatments, Uncategorized|0 Comments

Previous 12